13 completed, 4 active not recruiting, 1 recruiting, 1 terminated. 20 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 13, Active not recruiting 4, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 2, Withdrawn 1 |
Follow reolysin: new trials by email Literature Review of reolysin trials Research Report on reolysin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC | Phase 2 | Recruiting | Oncolytics Biotech | 60 | 2026-04-30 | 2026-11-05 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 10 | 2022-10-07 | 2026-05-13 |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel - Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified | Phase 1 / Phase 2 | Active not recruiting | Oncolytics Biotech | 122 | 2021-10-27 | 2026-05-19 |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study Pelareorep, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma | Phase 2 | Active not recruiting | Mridula George, MD | 25 | 2020-07-13 | 2025-04-04 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Paclitaxel, Pelareorep, Avelumab - Breast Cancer Metastatic | Phase 2 | Active not recruiting | Oncolytics Biotech | 48 | 2020-06-10 | 2025-01-16 |
| Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Pembrolizumab, Wild-type Reovirus - Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 2 | Terminated | Northwestern University | 17 | 2018-11-14 | 2022-10-05 |
| REO13 Melanoma With of Without GM-CSF Reolysin, GM-CSF - Melanoma, Cancer of Skin | Phase 1 / Phase 2 | Withdrawn | University of Leeds | 2017-10-01 | 2018-05-04 | |
| A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Paclitaxel, Reolysin - Metastatic Breast Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 81 | 2013-02-20 | 2023-08-04 |
| Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone - Prostate Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 85 | 2012-12-14 | 2023-08-04 |
| Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin - Non Small Cell Lung Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 166 | 2012-12-10 | 2023-08-04 |
| Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab - Colorectal Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 109 | 2012-10-26 | 2023-08-23 |
| Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Paclitaxel, Pelareorep - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 108 | 2010-12-06 | 2020-09-16 |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 73 | 2010-12-01 | 2018-03-09 |
| A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma REOLYSIN, Gemcitabine - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Completed | Oncolytics Biotech | 34 | 2009-10-01 | 2015-04-10 |
| A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung REOLYSIN, Paclitaxel, Carboplatin - Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | Phase 2 | Completed | Oncolytics Biotech | 32 | 2009-10-01 | 2016-03-31 |
| Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma REOLYSIN, Carboplatin, Paclitaxel - Metastatic Melanoma | Phase 2 | Completed | Oncolytics Biotech | 14 | 2009-09-01 | 2015-04-10 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation REOLYSIN®, Carboplatin, Paclitaxel - Carcinoma, Non-small Cell Lung | Phase 2 | Completed | Oncolytics Biotech | 37 | 2009-03-01 | 2015-12-02 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma REOLYSIN®, Carboplatin, Paclitaxel - Carcinoma, Squamous Cell of the Head and Neck | Phase 2 | Completed | Oncolytics Biotech | 14 | 2008-08-01 | 2014-11-04 |
| Viral Therapy in Treating Patients With Metastatic Melanoma wild-type reovirus - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2008-04-01 | 2014-04-22 |
| Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung REOLYSIN® - Osteosarcoma, Ewing Sarcoma Family Tumors | Phase 2 | Completed | Oncolytics Biotech | 53 | 2007-06-01 | 2014-10-02 |
Carcinoma (3) · Melanoma (3) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Fibrosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Multiple Myeloma (1) · Osteosarcoma (1) · Ovarian Neoplasms (1)
Oncolytics Biotech (9) · Canadian Cancer Trials Group (4) · National Cancer Institute (NCI) (3) · Mridula George, MD (1) · Northwestern University (1) · University of Leeds (1) · University of Southern California (1)
United States (14) · Canada (4) · Germany (1)
Alain Mita, MD (1) · Anne Noonan (1) · Bernhard Eigl (1) · David E Cohn (1) · Derek Jonker (1) · Devalingam Mahalingam (1) · Devalingam Mahalingam, MD, PhD (1) · Donald G Morris (1) · Evanthia Galanis (1) · Karl Mettinger, MD, PhD (1) · Kevin R Kelly, MD (1) · Miguel Villalona, MD (1) · Monica Mita, MD (1) · Mridula A George (1) · Patricia Tang (1)
PMID 26719427, PMID 27039845, PMID 29027598, PMID 29186319, PMID 29487723, PMID 29653857, PMID 29748010, PMID 37443348
N01CM00070 (2), N01CM62207 (1), P30CA014089 (1), P30CA016058 (1), P30CA060553 (1), P30CA072720 (1), U10CA027469 (1), U10CA180868 (1)